Acadia Pharmaceuticals (ACAD) Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Current Assets history runs 17 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, Current Assets rose 25.84% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 25.84% YoY), while the FY2025 annual figure was $1.1 billion, up 13.19% from the prior year.
• Current Assets for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Current Assets was $1.1 billion in Q1 2026, with the low at $492.6 million in Q2 2023.
• The 5-year median for Current Assets is $675.3 million (2024), against an average of $730.1 million.
• The sharpest annual moves came in 2022 and 2024: Current Assets retreated 19.55% in 2022, then soared 57.92% in 2024.
• Acadia Pharmaceuticals' Current Assets stood at $507.9 million in 2022, then increased by 21.3% to $616.1 million in 2023, then soared by 52.29% to $938.3 million in 2024, then gained by 13.19% to $1.1 billion in 2025, then advanced by 3.19% to $1.1 billion in 2026.
• Business Quant data shows ACAD's Current Assets at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.